December 18, 2020
December 18, 2020 – The U.S. FDA has approved Orgovyx TM (relugolix), manufactured by Myovant
Sciences, as the first oral hormone therapy indicated to treat advanced prostate
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
News
December 18, 2020
December 18, 2020 The U.S. FDA has approved a new indication for Tagrisso® (osimertinib),
manufactured by AstraZeneca. The drug is now indicated to provide adjuvant treatment
December 18, 2020
December 18, 2020 – The U.S. FDA has approved a new indication for Xpovio® (selinexor), manufactured by Karyopharm. The drug is now indicated for use in combination with bortezomib and
December 17, 2020
December 17, 2020 – The U.S. FDA has approved RiabniTM (rituximab-arrx), manufactured by Amgen, as
the third biosimilar for Genentech’s Rituxan® (rituximab). Riabni is indicated to treat certain
December 16, 2020
December 16, 2020 – The U.S. FDA has approved MargenzaTM (margetuximab-cmkb), manufactured by
MacroGenics, for use in combination with chemotherapy to treat adults who have
December 15, 2020
December 15, 2020 – The U.S. FDA has approved Klisyri® (tirbanibulin), manufactured by Almirall, to
provide topical treatment of actinic keratosis (AK) on the face or scalp. Klisyri is a novel
December 15, 2020
December 15, 2020 – Morton Grove Pharmaceuticals has issued a voluntary recall of four batches of
Hydroxyzine Hydrochloride (HCl) Oral Solution, USP (Syrup), 10mg/5mL due to an impurity.
December 14, 2020
December 14, 2020 – The U.S. FDA has approved ThyquidityTM (levothyroxine) oral solution, manufactured by VistaPharm, to provide replacement therapy for primary (thyroidal), secondary